false 0001763950 0001763950 2025-01-06 2025-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 6, 2025

 

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39318   46-3973463

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1920 McKinney Avenue, 7th Floor

Dallas, Texas

   75201
(Address of Principal Executive Offices)   (Zip Code)

 

(972) 277-1136

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: Common Stock

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value   LTRN   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 6, 2025, Lantern Pharma Inc.’s (the “Company’s) Board of Directors approved the amendment of the employment agreement, as amended (the “Employment Agreement”) for Kishor G. Bhatia, Chief Scientific Officer, to (i) extend the term of the Employment Agreement until January 15, 2026, (ii) adjust the minimum hours devoted by Dr. Bhatia per week to the scientific, clinical and therapeutic development operations and affairs of the Company to 24 hours per week, and (iii) proportionately adjust Dr. Bhatia’s annual base salary to $189,600, with such adjustment to take effect with the first pay period in January 2025.

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lantern Pharma Inc.,
  A Delaware Corporation
   
Dated: January 10, 2025 By: /s/ David R. Margrave
    David R. Margrave, Chief Financial Officer

 

3

 

v3.24.4
Cover
Jan. 06, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 06, 2025
Entity File Number 001-39318
Entity Registrant Name Lantern Pharma Inc.
Entity Central Index Key 0001763950
Entity Tax Identification Number 46-3973463
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1920 McKinney Avenue
Entity Address, Address Line Two 7th Floor
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75201
City Area Code (972)
Local Phone Number 277-1136
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol LTRN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Lantern Pharma Charts.
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Lantern Pharma Charts.